tyrosine kinase inhibitor

Targeted Radionuclide Boosts Survival in Pancreatic Tumors

[ad_1] BARCELONA—In sufferers with inoperable progressive pancreatic most cancers, a focused radionuclide, lutetium-octreotate (OCLU), exhibits almost double the 12-month progression-free…

Read More »